[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,469,803
  • Shares Outstanding, K 125,083
  • Annual Sales, $ 376,070 K
  • Annual Income, $ -16,140 K
  • EBIT $ 3 M
  • EBITDA $ 6 M
  • 60-Month Beta 1.48
  • Price/Sales 9.57
  • Price/Cash Flow N/A
  • Price/Book 18.98

Options Overview Details

View History
  • Implied Volatility 61.40% (-2.60%)
  • Historical Volatility 41.66%
  • IV Percentile 24%
  • IV Rank 12.91%
  • IV High 139.00% on 03/18/26
  • IV Low 49.90% on 06/15/26
  • Expected Move (DTE 5) 0.51 (1.84%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 160
  • Volume Avg (30-Day) 311
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 9,703
  • Open Int (30-Day) 8,670
  • Expected Range 27.23 to 28.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.07
  • Number of Estimates 2
  • High Estimate $0.09
  • Low Estimate $0.04
  • Prior Year $-0.13
  • Growth Rate Est. (year over year) +153.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.94 +20.90%
on 06/11/26
29.84 -7.04%
on 07/09/26
+4.51 (+19.41%)
since 06/10/26
3-Month
19.30 +43.77%
on 05/19/26
29.84 -7.04%
on 07/09/26
+3.53 (+14.58%)
since 04/10/26
52-Week
13.69 +102.56%
on 08/08/25
31.77 -12.68%
on 12/08/25
+12.47 (+81.66%)
since 07/10/25

Most Recent Stories

More News
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027 Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label...

ARQT : 27.74 (-3.61%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 27.74 (-3.61%)
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications

Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis Connects eligible individuals...

ARQT : 27.74 (-3.61%)
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use...

ARQT : 27.74 (-3.61%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 27.74 (-3.61%)
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology

Expert recommendations focused on the diagnosis and management of genital psoriasis across age groups including pediatric, adult, and older populations This is the second published manuscript from the...

ARQT : 27.74 (-3.61%)
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference

WESTLAKE VILLAGE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

ARQT : 27.74 (-3.61%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 27.74 (-3.61%)
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

Q1 2026 net product revenue for ZORYVE ® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 Continued strong demand for ZORYVE despite typical...

ARQT : 27.74 (-3.61%)
Arcutis Reports Tomorrow Having Already Told Investors Exactly What Growth to Expect

Barchart Research What to Expect from ARQT Earnings ARQT Generated May 5, 2026 Current Price $23.42 EPS Estimate $$-0.02 Consensus Rating Moderate Buy Average Move 7.56% Arcutis Reports Tomorrow Having...

ARQT : 27.74 (-3.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 30.85
2nd Resistance Point 29.91
1st Resistance Point 28.83
Last Price 27.74
1st Support Level 26.81
2nd Support Level 25.87
3rd Support Level 24.79

See More

52-Week High 31.77
Last Price 27.74
Fibonacci 61.8% 24.87
Fibonacci 50% 22.73
Fibonacci 38.2% 20.60
52-Week Low 13.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.